APA

Schneider V., Zhang L., Bullinger L., Rojewski M., Hofmann S., Wiesneth M., Schrezenmeier H., Götz M., Botzenhardt U., Barth T. F. E., Döhner K., Döhner H. & Greiner J. (20141007). Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy. : Leukemia.

Chicago

Schneider V, Zhang L, Bullinger L, Rojewski M, Hofmann S, Wiesneth M, Schrezenmeier H, Götz M, Botzenhardt U, Barth T F E, Döhner K, Döhner H and Greiner J. 20141007. Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy. : Leukemia.

Harvard

Schneider V., Zhang L., Bullinger L., Rojewski M., Hofmann S., Wiesneth M., Schrezenmeier H., Götz M., Botzenhardt U., Barth T. F. E., Döhner K., Döhner H. and Greiner J. (20141007). Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy. : Leukemia.

MLA

Schneider V, Zhang L, Bullinger L, Rojewski M, Hofmann S, Wiesneth M, Schrezenmeier H, Götz M, Botzenhardt U, Barth T F E, Döhner K, Döhner H and Greiner J. Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy. : Leukemia. 20141007.